Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Tenax Therapeutics, Inc. (NASDAQ: TENX).

Full DD Report for TENX

You must become a subscriber to view this report.


Recent News from (NASDAQ: TENX)

Tenax Therapeutics to Present at Upcoming Investor Conferences
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that company management will present at the following upcoming investor conferences: Event: The Micr...
Source: Business Wire
Date: September, 20 2018 08:30
Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that the Company will participate in the H.C. Wainwright 20 th Annual Global Investment Conference, which...
Source: Business Wire
Date: August, 29 2018 08:30
Tenax's levosimendan shows renal benefit in heart failure patients; shares up 1% premarket
Ultra-thinly traded nano cap Tenax Therapeutics (NASDAQ: TENX ) is up  1%  premarket on light volume in response to results from a study evaluating the effects of levosimendan on kidney function in patients with heart failure (HF). The data were just published in the Journal of ...
Source: SeekingAlpha
Date: August, 28 2018 09:08
Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients
Results indicate levosimendan increases glomerular filtration rate (GFR) Levosimendan may be a preferred drug for heart failure patient with impaired renal function Tenax Therapeutics, Inc. (NASDAQ: TENX) today announced the results of a new study titled "Differential ...
Source: Business Wire
Date: August, 28 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-101.551.351.681.31751,175,923
2018-12-072.021.445.121.4013,927,075
2018-12-061.871.682.181.62381,214
2018-12-052.001.952.081.90168,114
2018-12-042.001.99652.081.90153,160

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-071,410,8312,714,22551.9791Short
2018-12-0651,29171,01772.2236Short
2018-12-0426,22930,47886.0588Short
2018-12-039,61110,60090.6698Short
2018-11-3030,73346,60265.9478Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TENX.


About Tenax Therapeutics, Inc. (NASDAQ: TENX)

Logo for Tenax Therapeutics, Inc. (NASDAQ: TENX)

Not available

 

Contact Information

 

 

Current Management

  • Chris J. Stern / CEO
  • Michael B. Jebsen / CFO, EVP, Fin., Secretary
  • William Chatfield /
  • Rene Eckert /
  • Gregory Pepin /

Current Share Structure

  • Market Cap: $8,596,783 - 05/18/2018
  • Issue and Outstanding: 1,428,037 - 03/28/2018

 


Recent Filings from (NASDAQ: TENX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 05 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: May, 23 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 15 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 03 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018

 

 


Daily Technical Chart for (NASDAQ: TENX)

Daily Technical Chart for (NASDAQ: TENX)


Stay tuned for daily updates and more on (NASDAQ: TENX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: TENX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TENX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TENX and does not buy, sell, or trade any shares of TENX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/